Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO2011011376 - METHODS FOR THE PREPARATION AND USE OF AQUEOUS SOLUTIONS OF MAGNESIUM VALPROATE HYDRATE AND L-CARNITINE

Publication Number WO/2011/011376
Publication Date 27.01.2011
International Application No. PCT/US2010/042547
International Filing Date 20.07.2010
IPC
A61K 31/205 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
A61P 25/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
08Antiepileptics; Anticonvulsants
12for grand-mal
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
CPC
A61K 31/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
20having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
A61K 31/205
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
A61K 31/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
22of acyclic acids, e.g. pravastatin
A61K 9/0095
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0087Galenical forms not covered by A61K9/02 - A61K9/7023
0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Applicants
  • BIOLINK LIFE SCIENCES, INC. [US]/[US] (AllExceptUS)
  • NELSON, Deanna J. [US]/[US] (UsOnly)
Inventors
  • NELSON, Deanna J.
Agents
  • ARENSON, Tanya A.
Priority Data
12/505,84920.07.2009US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR THE PREPARATION AND USE OF AQUEOUS SOLUTIONS OF MAGNESIUM VALPROATE HYDRATE AND L-CARNITINE
(FR) PROCÉDÉS POUR LA PRÉPARATION ET L'UTILISATION DE SOLUTIONS AQUEUSES D'HYDRATE DE VALPROATE DE MAGNÉSIUM ET DE L-CARNITINE
Abstract
(EN)
The present invention relates to methods for preparing liquid valproate compositions comprising solutions of a magnesium valproate and L-carnitine in water and administering said compositions to a subject in need of treatment with valproate and L-carnitine. The compositions of the invention are particularly useful treatments for infants, young children, women of child-bearing age, the aging, institutionalized patients, and patients having dysphagia who are receiving valproate treatment and are at high risk for valproate-related L-carnitine deficiency and cellular dysfunction and hepatotoxicity related thereto.
(FR)
La présente invention concerne des procédés pour préparer des compositions de valproate liquides qui comprennent des solutions d'un valproate de magnésium et de L-carnitine dans de l'eau et pour administrer lesdites compositions à un patient nécessitant un traitement à base de valproate et de L-carnitine. Les compositions de l'invention s'avèrent être des traitements particulièrement utiles pour des nourrissons, des enfants en bas âge, les femmes en âge de porter un enfant, les patients âgés et vivant dans un établissement, et les patients souffrant de dysphagie qui reçoivent un traitement à base de valproate et qui présentent un risque élevé de déficience en L-carnitine associée au valproate ainsi qu'un dysfonctionnement cellulaire et une hépatotoxicité associée.
Also published as
Latest bibliographic data on file with the International Bureau